Inspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). The company's primary product is the Inspire system, a closed-loop neurostimulation technology that monitors breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. This implantable therapy is indicated for patients with moderate to severe OSA who do not tolerate continuous positive airway pressure (CPAP). The company sells its system to hospitals and ambulatory surgery centers in the United States and select European countries through a direct sales organization, while utilizing distributors in Japan and Singapore. Reimbursement in the U.S. is provided by commercial insurance providers, Medicare, and the Veterans Health Administration. The company was formed in 2007 when the Inspire technology and associated intellectual property were spun out of Medtronic.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage inspiresleep.com
Sector Healthcare IR page investors.inspiresleep.com/overview/default.aspx
Tags
obstructive sleep apnea, neurostimulation, hypoglossal nerve stimulation, implantable devices, sleep medicine, ent surgery, closed-loop systems, Inspire system, Inspire therapy, Inspire implant, Inspire remote, Inspire app, ADHERE registry, STAR trial, Medtronic
Press page —

Metrics

Valuation  
Market cap $ 2.007B
Market cap (USD) $ 2.007B
P/E 20.70
PEG —
P/BV 2.43
P/S 2.28
P/OCF 14.87
P/FCF 20.51
Dividend yield —
Turnover / mcap —
Returns  
ROE 19.8%
ROI 20.6%
ROIC 7.2%
Profit margin 15.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 11
Quality score 58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 911.981M 802.804M 624.799M 407.856M 233.394M 115.381M 82.05M 50.593M 28.567M
Net profit 145.422M 53.509M -21.153M -44.881M -42.042M -57.203M -33.243M -21.828M -17.511M
Free cash flow 78.477M 91.123M 1.024M 2.473M -24.787M -55.5M -35.585M -18.944M -16.203M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 92.23 185.38 203.43 251.88 230.06 188.09 74.21 42.25 —
Price performance 12m -0.5 -0.09 -0.19 0.09 0.22 1.53 0.76 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 3.86M 6.67M 13.1M 25.1M 34.2M 61.2M 89.9M 93.1M 120M
↳ YoY growth +72.8% +97.0% +90.9% +36.4% +79.1% +46.8% +3.5% +28.6%
↳ 5y CAGR +73.8% +68.2% +47.9% +36.7%
Lease liabilities (USD) — — 0.00 828,000 5.89M 9.11M 8.87M 24.8M 31.8M 32.2M
Cash and deposits (USD) 6.69M 8.96M 97.3M 22.9M 191M 214M 442M 186M 150M 105M
Right-of-use assets (USD) — — 1.8M 915,000 5.81M 7.92M 6.88M 22.7M 23.3M 23.5M
Cash flow detail
Operating cash flow (USD) -17.9M -15.8M -18.7M -32.8M -53M -20.1M 11.6M 24.7M 130M 117M
Purchases of property, plant and equipment (USD) -306,000 -412,000 -250,000 -2.74M -2.46M -4.67M -9.1M -23.6M -39.1M -38.5M
Change in receivables (cash effect) (USD) -760,000 -1.77M -2.84M -6.48M -11.8M -9.24M -27M -30.2M -2.6M -26.2M
Change in inventories (cash effect) (USD) 612,000 -315,000 1M -3.17M -2.65M -8.75M 5.35M -22M -46.2M -65.2M
Change in payables (cash effect) (USD) -480,000 1.83M 439,000 1.03M 2.05M 4.78M 14.4M 9.3M 604,000 -3.75M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -75M -175M
Interest paid (cash effect) (USD) -1.23M -1.32M -2.02M -2.03M -1.89M -1.89M -2.32M 0.00 -22,000 -137,000
Income taxes paid (cash effect) (USD) — — — — — — — — — -8.32M
Share-based compensation (USD) 248,000 243,000 1.22M 6.2M 12.8M 26.2M 52M 82.5M 116M 130M
Operating cash flow before change in receivables (USD) -17.2M -14M -15.9M -26.4M -41.2M -10.9M 38.6M 54.9M 133M 143M
Free cash flow (OCF - PPE - intangibles) (USD) -18.3M -16.2M -18.9M -35.6M -55.5M -24.8M 2.47M 1.02M 91.1M 78.5M
Income detail
Research and development expense (USD) 7.09M 6.19M 7.39M 12.8M 26.1M 37.4M 68.6M 117M 114M 103M
↳ 5y CAGR +39.4% +61.8% +73.6% +54.8% +31.6%
Total comprehensive income (USD) -18.5M -17.5M -21.9M -33.1M -57.3M -42.1M -44.9M -20.3M 53.2M 145M
Comprehensive income to owners (USD) -18.5M -17.5M -21.9M -33.1M -57.3M -42.1M -44.9M -20.3M 53.2M 145M
Provision for credit losses (USD) — — — — — 57,000 -13,000 1.62M 957,000 923,000
Credit cost ratio (credit losses / average receivables) (%) — — — — — 0.2% 0.0% 2.1% 1.0% 0.9%
Reported Feb 26, 2019 Feb 26, 2019 Feb 25, 2020 Feb 25, 2020 Feb 24, 2021 Feb 9, 2024 Feb 10, 2025 Feb 10, 2025 Feb 10, 2025 Feb 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Financial Results

•Third quarter revenue of $206.7 million

•Third quarter diluted EPS of $(0.84); adjusted diluted EPS of $0.14

•Third quarter operating cash flow of $46.4 million

•AMA CPT® Editorial Panel approved new Category I CPT codes for single lead hypoglossal nerve stimulation, including Inspire V, set to take effect January 1, 2028

MINNEAPOLIS, MN - November 2, 2026 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2026.

“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic.

October 5, 2026

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2026 earnings call webcast . For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Inspire's Q3 2026 earnings call . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems

Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com .

Investor Contact

Brian Johnston or Louisa Smith

Gilmartin Group, LLC

[email protected]

Primary Logo

Source: Inspire Medical Systems

View All News

Inspire Medical Systems, Inc.

IR Contact

Brian Johnston or Louisa Smith

Gilmartin Group, LLC

Send us an email [email protected]

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Inspire Medical Systems, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Inspire Medical Systems, Inc. to send you the requested Investor Email Alert updates.

* Required

Investor Alert OptionsEmail Address * Investor Alert Options *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Company

For potential patients

Resources

Connect with an inspire therapy advisor

Connect now (opens in new tab)

© 2026 Inspire Medical Systems, Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Linkedin opens in a new window Instagram opens in a new window Facebook opens in a new window Twitter opens in a new window Youtube opens in a new window

October 1, 2026

MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the American Medical Association (AMA) CPT® Editorial Panel has approved the establishment of a new set of Current Procedural Terminology (CPT®) codes that accurately describe and include the Inspire V system. The new Category I codes are scheduled to take effect on January 1, 2028.

“This new CPT code language addresses the implantation of a single lead and an implantable pulse generator (IPG) including our recently launched Inspire V system,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “We appreciate the AMA creating dedicated codes that will create a clearer, more consistent path for coding and reimbursement, which we expect will reduce administrative burden for hospitals and physicians and support continued growth in patient access to Inspire therapy. The application received broad society support with special thanks to the American Academy of Otolaryngology-Head and the Neck Surgery (AAO-HNS), the American Academy of Sleep Medicine (AASM) and the International Surgical Sleep Society (ISSS) for their support addressing the need to act now to provide a permanent coding solution for the Inspire V system and other single lead hypoglossal nerve stimulation IPG therapies.”

With the new codes created, the Centers for Medicare & Medicaid Services (CMS) will conduct its standard process to determine the value for each new CPT code, which determines the payments for that service under Medicare. CMS typically requests the AMA Relative Value Scale Update Committee (RUC) to review specific codes and evaluate whether physician time, work and expenses for related services have changed over time.

Specialty societies, such as the AAO-HNS, may survey their members and make recommendations to the RUC based on the output from the rigorous methodology for these surveys. These surveys would collect information regarding physician work including both time and complexity, practice expenses including clinical staff and any required supplies and equipment, and liability insurance. Sufficient physicians are surveyed to ensure accuracy of data collected.

After collecting and reviewing the data, the RUC recommendation is provided to CMS who we expect would publish their proposed valuation in July 2027 with final valuations published in November 2027.

The new Category I CPT codes reflect a growing body of clinical evidence supporting therapies like Inspire’s closed-loop implantable device, Inspire V, which is designed to work with a patient’s natural breathing to help keep the airway open during sleep. With more than 140,000 patients treated and over a decade of clinical experience, Inspire is a well-established leader in the treatment of OSA.

About Inspire Medical Systems

Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the anticipated implementation and effective date of the newly approved CPT® codes and the potential impact of such codes on coding, reimbursement, patient access, and adoption of Inspire therapy. Forward-looking statements may be identified by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "will," and similar expressions.

These forward-looking statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these risks and uncertainties can be found under the caption "Risk Factors" in Inspire Medical Systems, Inc.'s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statements contained in this press release speak only as of the date hereof. Inspire undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Investor Contact

Brian Johnston or Louisa Smith

Gilmartin Group, LLC

[email protected]

Primary Logo

Source: Inspire Medical Systems

View All News

Inspire Medical Systems, Inc.

IR Contact

Brian Johnston or Louisa Smith

Gilmartin Group, LLC

Send us an email [email protected]

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Inspire Medical Systems, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Inspire Medical Systems, Inc. to send you the requested Investor Email Alert updates.

* Required

Investor Alert OptionsEmail Address * Investor Alert Options *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Company

For potential patients

Resources

Connect with an inspire therapy advisor

Connect now (opens in new tab)

© 2026 Inspire Medical Systems, Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Linkedin opens in a new window Instagram opens in a new window Facebook opens in a new window Twitter opens in a new window Youtube opens in a new window

Prompts

Inspire Medical Systems, Inc. (ticker INSP), listed in United States.

ETFs Holding Inspire Medical Systems, Inc.

ETF Weight in ETF Shares Market value As of
ARWG 2.60% 6,092 $ 383.735K Aug 31, 2026
LITL 0.47% 453 $ 26.913K Nov 17, 2026
SQLV 0.40% 2,543 $ 113.443K Jun 30, 2026
AFSM 0.09% 2,129 $ 125.866K Nov 16, 2026
FESM 0.08% 107,366 $ 4.79M Jun 30, 2026
VFVA 0.06% 9,750 $ 614.153K Aug 31, 2026
FMDE 0.06% 104,563 $ 4.665M Jun 30, 2026
AVSC 0.06% 30,599 $ 1.809M Nov 16, 2026
RESM 0.06% 47 $ 2,096.67 Jun 30, 2026
JMEE 0.03% 15,200 $ 903.032K Nov 17, 2026
FELV 0.02% 15,385 $ 686.325K Jun 30, 2026
RILA 0.02% 144 $ 7,230.24 Jul 31, 2026
DFAT 0.01% 73,099 $ 4.425M Nov 12, 2026
MKTN short -0.01% -326 $ -14.543K Jun 30, 2026
DXUV 0.01% 7,972 $ 482.625K Nov 12, 2026
DFAS 0.00% 26,089 $ 1.579M Nov 12, 2026
DFUS 0.00% 15,356 $ 929.652K Nov 12, 2026
DCOR 0.00% 27,144 $ 1.643M Nov 12, 2026
DFAC 0.00% 45,299 $ 2.742M Nov 12, 2026
DFSU 0.00% 1,210 $ 73.253K Nov 12, 2026
DFAU 0.00% 6,084 $ 368.325K Nov 12, 2026
MSLC 0.00% 510 $ 32.125K Aug 31, 2026
DFUV 0.00% 1,722 $ 104.25K Nov 12, 2026
EBI 0.00% 6 $ 377.94 Aug 31, 2026
AVUS 0.00% 5,426 $ 320.785K Nov 16, 2026
AVSU 0.00% 227 $ 13.42K Nov 16, 2026